Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses

This study has been completed.
Sponsor:
Collaborator:
Novo Nordisk A/S
Information provided by:
Profil Institut für Stoffwechselforschung GmbH
ClinicalTrials.gov Identifier:
NCT00513643
First received: August 8, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted

August 8, 2007
August 8, 2007
April 2002
Not Provided
AUC GIR 360-720 min [ Time Frame: at each dosing (6 times during the trial) ]
Same as current
No Changes Posted
  • PK endpoints such as C max/ins, t max/ins, AUC ins 0-120 min, AUC ins 360-720 min, AUC ins 0-720 min [ Time Frame: at each dosing visit (6 times during the study) ]
  • PD endpoints like GIR max, t max/GIR, AUC GIR 0-120 min, AUC GIR 0-720 min, t >2/GIR, early and late t 50%/GIR [ Time Frame: at each dosing visit (6 times during the study) ]
Same as current
Not Provided
Not Provided
 
Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses
Pharmacodynamic and Pharmacokinetic Properties of Insulin Aspart: Dose - Ranging vs. Human Soluble Insulin

The metabolic effect of three different doses of insulin aspart and human insulin are investigated with the euglycaemic glucose clamp technique.

Double-blind, randomized, 6-period cross-over study in 16 healthy subjects. Each patient participates in 6 euglycemic glucose clamp experiments each.

The time interval between the study days is 2 to 28 days. At the clamp visits, subjects are connected to a Biostator (MTB Medizintechnik, Ulm, Germany) and receive an intravenous human insulin infusion (rate of 0.15 mU/kg/min) over the duration of each experiment to prevent a rise in endogenous insulin secretion. After a baseline period of 2 h the trial drug (6, 12, or 24 U of either Insulin Aspart or regular human insulin in random order) are administered s.c. with a syringe into the abdominal wall. Glucose infusion rates (GIR) necessary to keep blood glucose concentrations close to the clamp level of 90 mg/dl (5 mmol/l) are administered and recorded by the Biostator every minute for a period of 12 h post-dosing. Blood samples are drawn at regular intervals for the analysis of C-peptide and (depending on the trial drug administered) serum insulin or serum Insulin Aspart concentrations (measured with specific ELISAs).

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus
  • Drug: insulin aspart
    6, 12, 24 U s.c.
    Other Name: Novorapid
  • Drug: human regular insulin
    6, 12 and 24 IU sc
    Other Name: Actrapid
  • Experimental: 1
    6 U insulin aspart
    Intervention: Drug: insulin aspart
  • Experimental: 2
    12 U insulin aspart
    Intervention: Drug: insulin aspart
  • Experimental: 3
    24 U insulin aspart
    Intervention: Drug: insulin aspart
  • Active Comparator: 4
    6 IU human regular insulin
    Intervention: Drug: human regular insulin
  • Active Comparator: 5
    12 IU human regular insulin
    Intervention: Drug: human regular insulin
  • Active Comparator: 6
    24 IU human regular insulin
    Intervention: Drug: human regular insulin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
June 2002
Not Provided

Inclusion criteria:

  • Signed informed consent obtained before any trial-related activities
  • Healthy subjects between 18 and 45 years inclusive
  • Considered generally healthy upon completion of medical history and physical examination
  • Body mass index (BMI) < 27 kg/m2
  • HbA1c < 6,1 %
  • Non-smoker for at least three months
  • Females of childbearing potential using acceptable methods of contraception, including tubal ligation, an intrauterine device (IUD), the oral contraceptive pill or barrier methods.

Exclusion Criteria:

  • Participation in any other clinical trial and receipt of any investigational drug within four weeks prior to this trial
  • Previous participation in this trial
  • Clinically significant abnormal haematology or biochemistry screening test
  • Any disease requiring use of non topical prescription medicines
  • Any serious systemic infectious disease that occurred in the four weeks prior to the first dose of test drug
  • Any intercurrent illness that may affect blood glucose
  • Current addiction to alcohol or substances of abuse as determined by the investigator
  • Known or suspected allergy against insulin or any component of the composition of the trial drug
  • Blood donation > 500 ml within the last nine weeks
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
  • If female, subject is pregnant or lactating
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00513643
ISPS_Dose-ranging
No
Not Provided
Profil Institut für Stoffwechselforschung GmbH
Novo Nordisk A/S
Principal Investigator: Tim Heise, MD Profil Institut für Stoffwechselforschung GmbH
Profil Institut für Stoffwechselforschung GmbH
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP